Back
to Program Summary
Module XXII - A Review of Mushroom Toxicity - PART II
INTRODUCTION
Welcome to the American Association of Poison
Control Center’s electronic continuing education program for specialists
in poison information. This fourteen-day module will provide a review of
mushroom toxicity.
release date - 7/24/99
most recent review date - 7/24/99
LEARNING OBJECTIVES
Upon completion of this AAPCC continuing education module, each participant will be able to:
1. Classify a given genus/species of mushroom as a member of one of the 8 major classes of toxic mushrooms.
2. Identify the toxin(s) responsible for human toxicity in each mushroom class.
3. Describe the mechanism of action and site of toxicity for each mushroom class.
4. Discuss the clinical manifestations of toxicity associated with exposure to each of the mushroom classes.
5. Discuss the management of the poisoned patient.
AUTHOR
Ursula K. Hopkins, Pharm.D.
REVIEW PANEL
Peter Ciancaglini, PharmD
Daniel J. Cobaugh, Pharm.D.
Prashant Joshi, MD
Ruth Lawrence, MD
Christine Stork, PharmD
John H. Trestrail III, R.Ph.
Paul Wax, MD
REFERENCES
Goldfrank LR. Mushrooms:Toxic and Hallucinogenic. In Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS (eds) Goldfrank’s Toxicologic Emergencies. Stamford: Appleton and Lange;1998:1207-19.
Kunkel DB. and Braitberg G. Mushrooms, in Haddad L, Shannon M, Winchester J (eds): Poisoning and Drug Overdose, 3rd edition. Philadelphia, WB Saunders, 1998: 365-374.
Lampe KF. Mushroom Poisoning in Children Updated. Paediatrician (1977) 6:289-299.
Lampe KF. Toxic Fungi. Ann. Rev. Pharmacol. Toxicol. (1979) 19:85-104.
Lampe KF. Differential Diagnosis of Poisoning
by North American Mushrooms, With Particular Emphasis on Amanita Phalloides-Like
Intoxication. Ann. of Emer. Med. (1987) 16(9); 956956-62.
AUTHOR DECLARATION INFORMATION
As an accredited CME sponsor, the University of
Rochester Office of Continuing Professional Education requires that its
authors comply with ACCME Standards for Commercial Support of CME.
All authors are required to disclose any significant financial interest
or relationship that they may have with a supporting company or the manufacturer(s)
of any commercial product/service that will be discussed in the materials
they present.
ACCME STANDARDS OF COMMERCIAL SUPPORT OF CME
These standards require that materials be free
of commercial bias and that any information regarding commercial products/services
be based on scientific methods generally accepted by the medical community.
When discussing therapeutic options, it is our preference that only generic
names be used. If it is necessary to use a trade name, then those
of several companies must be used. Further, should the presentation
include discussion of any unlabelled or investigational use of a commercial
product, the author required to disclose this to the reader.
AUTHOR DECLARATIONS
NO DISCLOSURES have been made by the author(s)
of this module that could be perceived as a real or apparent conflict of
interest in the context of the subject of their presentation(s).
CERTIFICATION
The University of Rochester School of Medicine and Dentistry is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The University of Rochester School of Medicine and Dentistry designates this educational activity for a maximum of 3.0 hours in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
This CME activity was planned and
produced in accordance with the Essentials and Standards of the Accreditation
Council for Continuing Medical Education.